Dataset from A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine

The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.

本研究旨在对比接受雷莫芦单抗（ramucirumab）联合FOLFIRI方案，或安慰剂联合FOLFIRI方案治疗的转移性结直肠癌（metastatic colorectal cancer）受试者的总生存期（overall survival）。